These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Historical series of patients with visceral leishmaniasis treated with meglumine antimoniate in a hospital for tropical diseases, Maceió-AL, Brazil. Silveira LJ; Rocha TJ; Ribeiro SA; Pedrosa CM Rev Inst Med Trop Sao Paulo; 2015; 57(1):33-8. PubMed ID: 25651324 [TBL] [Abstract][Full Text] [Related]
45. Treatment of resistant visceral leishmaniasis with interferon gamma in combination with liposomal amphotericin B and allopurinol. Khodabandeh M; Rostami A; Borhani K; Gamble HR; Mohammadi M Parasitol Int; 2019 Oct; 72():101934. PubMed ID: 31129197 [TBL] [Abstract][Full Text] [Related]
46. Visceral leishmaniasis: A leucaemia mimicker: A case report. Rathod SG; Chozakade A; Akhoon T; Jalid A; Roshan R Trop Doct; 2022 Oct; 52(4):586-587. PubMed ID: 35880300 [TBL] [Abstract][Full Text] [Related]
47. Efficacy and safety of amphotericin B deoxycholate versus N-methylglucamine antimoniate in pediatric visceral leishmaniasis: an open-label, randomized, and controlled pilot trial in Brazil. Borges MM; Pranchevicius MC; Noronha EF; Romero GA; Carranza-Tamayo CO Rev Soc Bras Med Trop; 2017; 50(1):67-74. PubMed ID: 28327804 [TBL] [Abstract][Full Text] [Related]
48. Visceral leishmaniasis in HIV-1-infected individuals: a common opportunistic infection in Spain? Medrano FJ; Hernández-Quero J; Jiménez E; Pineda JA; Rivero A; Sánchez-Quijano A; Velez ID; Viciana P; Castillo R; Reyes MJ AIDS; 1992 Dec; 6(12):1499-503. PubMed ID: 1362880 [TBL] [Abstract][Full Text] [Related]
49. Pediatric visceral leishmaniasis in Tartous, Syria. Hamwi AO; Mohammad AA; Hamwi SO; Mohammad RA; Shahin KY Avicenna J Med; 2020; 10(4):223-226. PubMed ID: 33437694 [TBL] [Abstract][Full Text] [Related]
50. Short-course Regimens of Liposomal Amphotericin B for the Treatment of Mediterranean Visceral Leishmaniasis in Children: An 11-year Retrospective Study at a Tertiary Care Center. Krepis P; Argyri I; Krepi A; Syrmou A; Spyridis N; Tsolia M Pediatr Infect Dis J; 2017 Sep; 36(9):849-854. PubMed ID: 28399053 [TBL] [Abstract][Full Text] [Related]
51. [Liposomal amphotericin B as treatment for visceral leishmaniasis in Europe, 2009]. Rosenthal E; Delaunay P; Jeandel PY; Haas H; Pomares-Estran C; Marty P Med Mal Infect; 2009 Oct; 39(10):741-4. PubMed ID: 19783391 [TBL] [Abstract][Full Text] [Related]
52. Liposomal amphotericin B versus pentavalent antimony salts for visceral Leishmania in children. Apa H; Devrim İ; Bayram N; Deveci R; Demir-Özek G; Cartı ÖU Turk J Pediatr; 2013; 55(4):378-83. PubMed ID: 24292030 [TBL] [Abstract][Full Text] [Related]
53. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme. Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967 [TBL] [Abstract][Full Text] [Related]
54. A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience. Cascio A; di Martino L; Occorsio P; Giacchino R; Catania S; Gigliotti AR; Aiassa C; Iaria C; Giordano S; Colomba C; Polara VF; Titone L; Gradoni L; Gramiccia M; Antinori S J Antimicrob Chemother; 2004 Jul; 54(1):217-20. PubMed ID: 15150166 [TBL] [Abstract][Full Text] [Related]
55. Epidemiological, clinical and hematological profiles of visceral leishmaniasis among patients visiting Tefera Hailu Memorial Hospital, Northeast Ethiopia: a 4 year retrospective study. Debash H; Bisetegn H; Nigatie M; Abeje G; Feleke DG Sci Rep; 2023 Jan; 13(1):931. PubMed ID: 36650391 [TBL] [Abstract][Full Text] [Related]
56. Prognostic factors for death from visceral leishmaniasis in patients treated with liposomal amphotericin B in an endemic state in Brazil. Dias Tourinho B; Figueiredo Amâncio F; Lencine Ferraz M; Carneiro M Trans R Soc Trop Med Hyg; 2017 Apr; 111(4):163-171. PubMed ID: 28673017 [TBL] [Abstract][Full Text] [Related]
57. Visceral leishmaniasis after kidney transplantation: report of a new case and a review of the literature. Bouchekoua M; Trabelsi S; Ben Abdallah T; Khaled S Transplant Rev (Orlando); 2014 Jan; 28(1):32-5. PubMed ID: 24321305 [TBL] [Abstract][Full Text] [Related]
58. Clinical and Epidemiologic Features of Visceral Leishmaniasis in Children in Southwestern China: A Retrospective Analysis From 2001 to 2015. Miao R; Wang Z; Guo Q; Wen Y; Liao Q; Zhu Y; Shu M; Wan C Pediatr Infect Dis J; 2017 Jan; 36(1):9-12. PubMed ID: 27749663 [TBL] [Abstract][Full Text] [Related]
59. Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis. Shirzadi MR Res Rep Trop Med; 2019; 10():11-18. PubMed ID: 31118866 [TBL] [Abstract][Full Text] [Related]
60. Pediatric Visceral Leishmaniasis Caused by Leishmania infantum in Northern Cyprus. Sayili A; Ozkan AT; Schallig HD Am J Trop Med Hyg; 2016 Dec; 95(6):1386-1388. PubMed ID: 27698271 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]